Futuximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | HER1 |
| Clinical data | |
| Other names | 992 DS |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6468H10002N1724O2055S46 |
| Molar mass | 146269.94 g·mol−1 |
Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.
This drug was developed by Symphogen.